Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated:  10/27/2015
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated: 10/27/2015
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated:  10/27/2015
Hospital Universitario Austral
mi
from
Derqui-Pilar,
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated: 10/27/2015
Hospital Universitario Austral
mi
from
Derqui-Pilar,
Click here to add this to my saved trials
Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients
Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients
Status: Enrolling
Updated:  10/28/2015
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients
Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients
Status: Enrolling
Updated: 10/28/2015
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/28/2015
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/28/2015
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/28/2015
Tower Cancer Research Foundation
mi
from
Beverly Hills, CA
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/28/2015
Tower Cancer Research Foundation
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/28/2015
Therapeutic Research Institute of Orange County
mi
from
Laguna Hills, CA
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/28/2015
Therapeutic Research Institute of Orange County
mi
from
Laguna Hills, CA
Click here to add this to my saved trials
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/28/2015
Rocky Mountain Blood and Marrow Transplant Program
mi
from
Denver, CO
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/28/2015
Rocky Mountain Blood and Marrow Transplant Program
mi
from
Denver, CO
Click here to add this to my saved trials
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/28/2015
Oncology & Hematology Assoc. of W. Broward
mi
from
Tamarac, FL
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/28/2015
Oncology & Hematology Assoc. of W. Broward
mi
from
Tamarac, FL
Click here to add this to my saved trials
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/28/2015
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/28/2015
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/28/2015
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/28/2015
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/28/2015
Northwestern University
mi
from
Chicago, IL
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/28/2015
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/28/2015
Orchard Research
mi
from
Skokie, IL
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/28/2015
Orchard Research
mi
from
Skokie, IL
Click here to add this to my saved trials
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/28/2015
University of Kentucky College of Medicine
mi
from
Lexington, KY
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/28/2015
University of Kentucky College of Medicine
mi
from
Lexington, KY
Click here to add this to my saved trials
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/28/2015
Montgomery Cancer Center
mi
from
Mt. Sterling, KY
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/28/2015
Montgomery Cancer Center
mi
from
Mt. Sterling, KY
Click here to add this to my saved trials
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/28/2015
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/28/2015
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/28/2015
Mayo Clinic Rochester
mi
from
Rochester, MN
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/28/2015
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/28/2015
Hattiesburg Clinic
mi
from
Hattiesburg, MS
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/28/2015
Hattiesburg Clinic
mi
from
Hattiesburg, MS
Click here to add this to my saved trials
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/28/2015
Jackson Oncology Associates
mi
from
Jackson, MS
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/28/2015
Jackson Oncology Associates
mi
from
Jackson, MS
Click here to add this to my saved trials
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/28/2015
Washington University School of Medicine
mi
from
St. Louis, MO
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/28/2015
Washington University School of Medicine
mi
from
St. Louis, MO
Click here to add this to my saved trials
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/28/2015
Hackensack University Medical Center
mi
from
Hackensack, NJ
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/28/2015
Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/28/2015
St. Vincents Comprehensive Cancer Center
mi
from
New York, NY
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/28/2015
St. Vincents Comprehensive Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/28/2015
Summa Health System
mi
from
Akron, OH
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/28/2015
Summa Health System
mi
from
Akron, OH
Click here to add this to my saved trials
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/28/2015
Gabrail Cancer Center
mi
from
Canton, OH
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/28/2015
Gabrail Cancer Center
mi
from
Canton, OH
Click here to add this to my saved trials
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/28/2015
Cleveland Clinic
mi
from
Cleveland, OH
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/28/2015
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/28/2015
Dayton Clinical Oncology Program
mi
from
Dayton, OH
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/28/2015
Dayton Clinical Oncology Program
mi
from
Dayton, OH
Click here to add this to my saved trials
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/28/2015
Signal Point Clinical Research Center, LLC
mi
from
Middletown, OH
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/28/2015
Signal Point Clinical Research Center, LLC
mi
from
Middletown, OH
Click here to add this to my saved trials
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/28/2015
Harrington Cancer Center
mi
from
Amarillo, TX
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/28/2015
Harrington Cancer Center
mi
from
Amarillo, TX
Click here to add this to my saved trials
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/28/2015
Texas Oncology Cancer Center
mi
from
Austin, TX
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/28/2015
Texas Oncology Cancer Center
mi
from
Austin, TX
Click here to add this to my saved trials
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/28/2015
M.D. Anderson Cancer Center
mi
from
Houston, TX
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/28/2015
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/28/2015
University of Calgary
mi
from
Calgary,
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/28/2015
University of Calgary
mi
from
Calgary,
Click here to add this to my saved trials
Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia
A Phase II Study of Combination Nilotinib and Hyper-CVAD in Patients Newly Diagnosed With Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia Blast-Phase Lymphoid Lineage
Status: Enrolling
Updated:  10/29/2015
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia
A Phase II Study of Combination Nilotinib and Hyper-CVAD in Patients Newly Diagnosed With Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia Blast-Phase Lymphoid Lineage
Status: Enrolling
Updated: 10/29/2015
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia
A Phase II Study of Combination Nilotinib and Hyper-CVAD in Patients Newly Diagnosed With Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia Blast-Phase Lymphoid Lineage
Status: Enrolling
Updated:  10/29/2015
The Mayo Clinic
mi
from
Rochester, MN
Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia
A Phase II Study of Combination Nilotinib and Hyper-CVAD in Patients Newly Diagnosed With Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia Blast-Phase Lymphoid Lineage
Status: Enrolling
Updated: 10/29/2015
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation
CD45A-Depleted Haploidentical Hematopoietic Progenitor Cell and Natural Killer Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation
Status: Enrolling
Updated:  10/29/2015
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation
CD45A-Depleted Haploidentical Hematopoietic Progenitor Cell and Natural Killer Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation
Status: Enrolling
Updated: 10/29/2015
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Effectiveness of Topical Thalidomide to Treat Chronic Graft-Versus-Host-Disease Related Stomatitis
Evaluation of Efficacy and Mechanisms of Topical Thalidomide for Chronic Graft-Versus-Host-Disease Related Stomatitis
Status: Enrolling
Updated:  10/29/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Effectiveness of Topical Thalidomide to Treat Chronic Graft-Versus-Host-Disease Related Stomatitis
Evaluation of Efficacy and Mechanisms of Topical Thalidomide for Chronic Graft-Versus-Host-Disease Related Stomatitis
Status: Enrolling
Updated: 10/29/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Effectiveness of Topical Thalidomide to Treat Chronic Graft-Versus-Host-Disease Related Stomatitis
Evaluation of Efficacy and Mechanisms of Topical Thalidomide for Chronic Graft-Versus-Host-Disease Related Stomatitis
Status: Enrolling
Updated:  10/29/2015
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Effectiveness of Topical Thalidomide to Treat Chronic Graft-Versus-Host-Disease Related Stomatitis
Evaluation of Efficacy and Mechanisms of Topical Thalidomide for Chronic Graft-Versus-Host-Disease Related Stomatitis
Status: Enrolling
Updated: 10/29/2015
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies
A Phase I Study of the Safety and Pharmacokinetics of Escalating Intravenous Doses of the Proteasome Inhibitor PR-171 in Patients With Hematological Malignancies
Status: Enrolling
Updated:  10/29/2015
Tower Cancer Research Foundation
mi
from
Beverly Hills, CA
Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies
A Phase I Study of the Safety and Pharmacokinetics of Escalating Intravenous Doses of the Proteasome Inhibitor PR-171 in Patients With Hematological Malignancies
Status: Enrolling
Updated: 10/29/2015
Tower Cancer Research Foundation
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies
A Phase I Study of the Safety and Pharmacokinetics of Escalating Intravenous Doses of the Proteasome Inhibitor PR-171 in Patients With Hematological Malignancies
Status: Enrolling
Updated:  10/29/2015
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies
A Phase I Study of the Safety and Pharmacokinetics of Escalating Intravenous Doses of the Proteasome Inhibitor PR-171 in Patients With Hematological Malignancies
Status: Enrolling
Updated: 10/29/2015
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies
A Phase I Study of the Safety and Pharmacokinetics of Escalating Intravenous Doses of the Proteasome Inhibitor PR-171 in Patients With Hematological Malignancies
Status: Enrolling
Updated:  10/29/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies
A Phase I Study of the Safety and Pharmacokinetics of Escalating Intravenous Doses of the Proteasome Inhibitor PR-171 in Patients With Hematological Malignancies
Status: Enrolling
Updated: 10/29/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies
A Phase I Study of the Safety and Pharmacokinetics of Escalating Intravenous Doses of the Proteasome Inhibitor PR-171 in Patients With Hematological Malignancies
Status: Enrolling
Updated:  10/29/2015
Weil Medical College of Cornell University
mi
from
New York, NY
Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies
A Phase I Study of the Safety and Pharmacokinetics of Escalating Intravenous Doses of the Proteasome Inhibitor PR-171 in Patients With Hematological Malignancies
Status: Enrolling
Updated: 10/29/2015
Weil Medical College of Cornell University
mi
from
New York, NY
Click here to add this to my saved trials
Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies
A Phase I Study of the Safety and Pharmacokinetics of Escalating Intravenous Doses of the Proteasome Inhibitor PR-171 in Patients With Hematological Malignancies
Status: Enrolling
Updated:  10/29/2015
Herbert Irving Comprehensive Cancer Center of Columbia University
mi
from
New York, NY
Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies
A Phase I Study of the Safety and Pharmacokinetics of Escalating Intravenous Doses of the Proteasome Inhibitor PR-171 in Patients With Hematological Malignancies
Status: Enrolling
Updated: 10/29/2015
Herbert Irving Comprehensive Cancer Center of Columbia University
mi
from
New York, NY
Click here to add this to my saved trials
LY353381 in Preventing Breast Cancer in Women With Hyperplasia
A Phase II Clinical Trial of a Selective Estrogen Receptor Modulator (LY353381*HCl) in High Risk Women With Fine Needle Aspiration Cytologic Evidence of Hyperplasia
Status: Enrolling
Updated:  10/30/2015
University of Kansas Medical Center
mi
from
Kansas City, KA
LY353381 in Preventing Breast Cancer in Women With Hyperplasia
A Phase II Clinical Trial of a Selective Estrogen Receptor Modulator (LY353381*HCl) in High Risk Women With Fine Needle Aspiration Cytologic Evidence of Hyperplasia
Status: Enrolling
Updated: 10/30/2015
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
LY353381 in Preventing Breast Cancer in Women With Hyperplasia
A Phase II Clinical Trial of a Selective Estrogen Receptor Modulator (LY353381*HCl) in High Risk Women With Fine Needle Aspiration Cytologic Evidence of Hyperplasia
Status: Enrolling
Updated:  10/30/2015
U.S. Oncology Research, Inc.
mi
from
Dallas, TX
LY353381 in Preventing Breast Cancer in Women With Hyperplasia
A Phase II Clinical Trial of a Selective Estrogen Receptor Modulator (LY353381*HCl) in High Risk Women With Fine Needle Aspiration Cytologic Evidence of Hyperplasia
Status: Enrolling
Updated: 10/30/2015
U.S. Oncology Research, Inc.
mi
from
Dallas, TX
Click here to add this to my saved trials
Thalidomide, Dexamethasone, and Clarithromycin in Treating Patients With Multiple Myeloma Previously Treated With Transplant
Maintenance Therapy With Thalidomide, Dexamethasone and Clarithromycin (Biaxin) Following Autologous/Syngeneic Transplant for Multiple Myeloma
Status: Enrolling
Updated:  10/30/2015
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Thalidomide, Dexamethasone, and Clarithromycin in Treating Patients With Multiple Myeloma Previously Treated With Transplant
Maintenance Therapy With Thalidomide, Dexamethasone and Clarithromycin (Biaxin) Following Autologous/Syngeneic Transplant for Multiple Myeloma
Status: Enrolling
Updated: 10/30/2015
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Phase II Study of TPA Plus Dexamethasone & CMT in Hematologic Malignancies
A Phase II Study of 12-O-tetradecanoylphorbol-13-acetate (TPA) Plus Dexamethasone & Choline Magnesium Trisalicylate in the Treatment of Patients With Relapsed/Refractory Acute Myelogenous Leukemia
Status: Enrolling
Updated:  11/2/2015
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Phase II Study of TPA Plus Dexamethasone & CMT in Hematologic Malignancies
A Phase II Study of 12-O-tetradecanoylphorbol-13-acetate (TPA) Plus Dexamethasone & Choline Magnesium Trisalicylate in the Treatment of Patients With Relapsed/Refractory Acute Myelogenous Leukemia
Status: Enrolling
Updated: 11/2/2015
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Bortezomib in Treating Patients With Lymphoproliferative Disorders
Phase II Study of PS-341 in Low Grade Lymphoproliferative Disorders
Status: Enrolling
Updated:  11/2/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Bortezomib in Treating Patients With Lymphoproliferative Disorders
Phase II Study of PS-341 in Low Grade Lymphoproliferative Disorders
Status: Enrolling
Updated: 11/2/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies
Conditioning for Hematopoietic Cell Transplantation With Fludarabine Plus Targeted IV Busulfan and GVHD Prophylaxis With Thymoglobulin, Tacrolimus and Methotrexate in Patients With Myeloid Malignancies
Status: Enrolling
Updated:  11/3/2015
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies
Conditioning for Hematopoietic Cell Transplantation With Fludarabine Plus Targeted IV Busulfan and GVHD Prophylaxis With Thymoglobulin, Tacrolimus and Methotrexate in Patients With Myeloid Malignancies
Status: Enrolling
Updated: 11/3/2015
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)
A Phase 3, Multicenter, Randomized, Open-Label, Study of Azacitidine (Vidaza®) Versus Conventional Care Regimens for the Treatment of Older Subjects With Newly Diagnosed Acute Myeloid Leukemia
Status: Enrolling
Updated:  11/4/2015
Massachusetts General Hospital
mi
from
Boston, MA
Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)
A Phase 3, Multicenter, Randomized, Open-Label, Study of Azacitidine (Vidaza®) Versus Conventional Care Regimens for the Treatment of Older Subjects With Newly Diagnosed Acute Myeloid Leukemia
Status: Enrolling
Updated: 11/4/2015
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)
A Phase 3, Multicenter, Randomized, Open-Label, Study of Azacitidine (Vidaza®) Versus Conventional Care Regimens for the Treatment of Older Subjects With Newly Diagnosed Acute Myeloid Leukemia
Status: Enrolling
Updated:  11/4/2015
M.D. Anderson Cancer Center
mi
from
Houston, TX
Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)
A Phase 3, Multicenter, Randomized, Open-Label, Study of Azacitidine (Vidaza®) Versus Conventional Care Regimens for the Treatment of Older Subjects With Newly Diagnosed Acute Myeloid Leukemia
Status: Enrolling
Updated: 11/4/2015
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)
A Phase 3, Multicenter, Randomized, Open-Label, Study of Azacitidine (Vidaza®) Versus Conventional Care Regimens for the Treatment of Older Subjects With Newly Diagnosed Acute Myeloid Leukemia
Status: Enrolling
Updated:  11/4/2015
Prince of Wales Hospital
mi
from
Randwick,
Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)
A Phase 3, Multicenter, Randomized, Open-Label, Study of Azacitidine (Vidaza®) Versus Conventional Care Regimens for the Treatment of Older Subjects With Newly Diagnosed Acute Myeloid Leukemia
Status: Enrolling
Updated: 11/4/2015
Prince of Wales Hospital
mi
from
Randwick,
Click here to add this to my saved trials
Nuvigil in Treatment of Cancer-Related Fatigue in Chronic Myeloid Leukemia Patients
Nuvigil in Treatment of Cancer-Related Fatigue in Chronic Myeloid Leukemia (CML) on Imatinib, Dasatinib, Nilotinib (or Any Other FDA Approved TKI for CML)
Status: Enrolling
Updated:  11/4/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Nuvigil in Treatment of Cancer-Related Fatigue in Chronic Myeloid Leukemia Patients
Nuvigil in Treatment of Cancer-Related Fatigue in Chronic Myeloid Leukemia (CML) on Imatinib, Dasatinib, Nilotinib (or Any Other FDA Approved TKI for CML)
Status: Enrolling
Updated: 11/4/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials